Ellison GW - Search Results

1

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Cutter GR, et al. Among authors: ellison gw. Brain. 1999 May;122 ( Pt 5):871-82. doi: 10.1093/brain/122.5.871. Brain. 1999. PMID: 10355672

2

Clinical outcomes assessment in multiple sclerosis.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321. Ann Neurol. 1996. PMID: 8797541 Review.

3

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Ann Neurol. 1997 Sep;42(3):379-82. doi: 10.1002/ana.410420318. Ann Neurol. 1997. PMID: 9307263

4

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.

Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, Holevoet-Howson MI, Lerner CD, Frane MV, Pettler-Jennings P. Ellison GW, et al. Neurology. 1989 Aug;39(8):1018-26. doi: 10.1212/wnl.39.8.1018. Neurology. 1989. PMID: 2668784 Clinical Trial.

5

Design strategies in multiple sclerosis clinical trials. The Cyclosporine Multiple Sclerosis Study Group.

Ellison GW, Myers LW, Leake BD, Mickey MR, Ke D, Syndulko K, Tourtellotte WW. Ellison GW, et al. Ann Neurol. 1994;36 Suppl:S108-12. doi: 10.1002/ana.410360725. Ann Neurol. 1994. PMID: 8017868

6

Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. Reliability, validity and sensitivity to disease progression. Multiple Sclerosis Study Group.

Syndulko K, Ke D, Ellison GW, Baumhefner RW, Myers LW, Tourtellotte WW. Syndulko K, et al. Among authors: ellison gw. Mult Scler. 1996 Oct;2(3):142-56. doi: 10.1177/135245859600200305. Mult Scler. 1996. PMID: 9345379 Clinical Trial.

7

Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Its correlation with clinical parameters, evoked potentials, and intra-blood-brain barrier IgG synthesis.

Baumhefner RW, Tourtellotte WW, Syndulko K, Waluch V, Ellison GW, Meyers LW, Cohen SN, Osborne M, Shapshak P. Baumhefner RW, et al. Among authors: ellison gw. Arch Neurol. 1990 Jan;47(1):19-26. doi: 10.1001/archneur.1990.00530010027014. Arch Neurol. 1990. PMID: 2294889

8

Evoked potentials predict the clinical changes in a multiple sclerosis drug study.

Nuwer MR, Packwood JW, Myers LW, Ellison GW. Nuwer MR, et al. Among authors: ellison gw. Neurology. 1987 Nov;37(11):1754-61. doi: 10.1212/wnl.37.11.1754. Neurology. 1987. PMID: 3313101 Clinical Trial.

9

An illness severity score for multiple sclerosis.

Mickey MR, Ellison GW, Myers LW. Mickey MR, et al. Among authors: ellison gw. Neurology. 1984 Oct;34(10):1343-7. doi: 10.1212/wnl.34.10.1343. Neurology. 1984. PMID: 6541306

10

The long march of the cerebrospinal fluid profile indicative of clinical definite multiple sclerosis; and still marching.

Tourtellotte WW, Baumhefner RW, Syndulko K, Shapshak P, Osborne M, Rubinshtein G, Newton L, Ellison G, Myers L, Rosario I, et al. Tourtellotte WW, et al. J Neuroimmunol. 1988 Dec;20(2-3):217-27. doi: 10.1016/0165-5728(88)90163-4. J Neuroimmunol. 1988. PMID: 3198746

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page